Advancing in vitro skin sensitization testing with GARD® and EpiSensA
Exciting news from the SenzaGen Group! Our Group company VitroScreen has recently validated and implemented the in vitro skin sensitization assay EpiSensA (OECD TG 442D).
With this new achievement, we are proud to be the first service provider in Europe offering both GARDskin (OECD TG 442E) and EpiSensA (OECD TG 442D) for in vitro skin sensitization testing!
By integrating GARD®skin’s genomic biomarker approach with EpiSensA’s reconstructed human epidermis (RhE) model, we provide a complementary platform to address KE2 and KE3 in the AOP and strengthen your skin sensitization testing strategy. This synergy enhances predictivity and supports regulatory compliance, reinforcing our commitment to advancing NAMs for in vitro skin sensitization testing.
Want to learn how this can support your safety assessments?
